Pfizer/BioNTech’s corona vaccine is fast becoming the best-selling product of all time in pharma. And that does not benefit either company in the least. Pfizer expects full-year revenues of 28.8 billion euros from the successful vaccine it developed together with its German biotech partner. And it doesn’t stop there: BioNTech and Pfizer recently signed contracts to deliver about 2.2 billion doses this year. Next year and the coming years this will involve at least 1 billion doses per year, including so-called booster shots. All that income is distributed, so partner BioNTech is now also raising its turnover expectations for this year to 15.9 billion euros. This is evident from the quarterly figures.
–
Related posts:
Jack Wolfskin strategically realigns the brand › sales management
The Castle of Sandro: A Legendary Cultural Center and Museum
Korea-Indonesia Summit: Strengthening Cooperation in Diplomacy, Security, and Future Industries
Due to the lack of semiconductors, it is not clear about car deliveries in Latvia as well
